Ryan Haumschild, PharmD, MS, MBA

A panel of experts on respiratory syncytial virus (RSV) introduce themselves and give an overview of patients who are most affected by RSV.

Experts in multiple sclerosis discuss overall patient satisfaction with current disease-modifying therapies for multiple sclerosis, highlighting the need for more therapies that stave off decline and disease progression.

Key opinion leaders discuss the most significant unmet needs in the current treatment landscape for multiple sclerosis.

Heidi Crayton, MD, and Maria Lopes, MD, discuss the limitations of using relapse rates as a critical endpoint in trials for patients with non-relapsing secondary progressive multiple sclerosis experiencing disease progression without relapse, explore methods to assess therapeutic benefit in this population, examine the relationship between cost of care and disease severity, and highlight the impact of decreased mobility and cognition on MS patients along with strategies for improvement.

Heidi Crayton, MD, and Maria Lopes, MD, discuss the impact of multiple sclerosis on patients, families, and caregivers, differentiate relapsing forms (relapsing-remitting and primary progressive) from non-relapsing forms (non-relapsing secondary progressive) in clinical practice, and highlight the key pathophysiological features of relapsing multiple sclerosis and the impact of progression independent of relapse activity (PIRA) after an initial demyelinating event.

A panel of experts share closing thoughts and advice for the management and uptake of HIV PrEP therapy.

Carl Schmid shares insight on the use of advocacy groups to help patients overcome barriers to access for HIV PrEP therapy.

Sean E. Bland, JD; Frank J. Palella, MD; and Carl Schmid explore organizational opportunities to improve access to HIV PrEP therapy and population health management strategies to improve PrEP uptake.

Carl Schmid discusses how the COVID-19 pandemic has amplified health care disparities and accessing HIV PrEP, and Frank J. Palella, MD, comments on the role of telehealth in improving access to PrEP.

Ryan Bitton, PharmD, MBA, provides a payer perspective on the importance of creating future health policies for HIV PrEP agents using real-world evidence and considering the total cost of care for patients.

Ryan Bitton, PharmD, MBA; Sean E. Bland, JD; Frank J. Palella, MD; and Carl Schmid comment on challenges in the implementation of USPSTF guidelines for HIV PrEP as well as existing unknowns with the guidance.

Frank J. Palella, MD, shares a provider perspective for steps to take in accordance with USPSTF guidelines for HIV PrEP to get patients appropriate medications, and Ryan Bitton, PharmD, MBA, shares a provider prospective on supporting expedited prior authorizations.

Sean E. Bland, JD, provides insight for when a health plan or issuer may use reasonable medical-management techniques, in accordance with USPSTF guidelines for HIV PrEP, and Ryan Bitton, PharmD, MBA, shares a payer perspective on utilization-management policies regarding PrEP.

Panelists look toward the future management of myelodysplastic syndromes with respect to novel agents and treatment pathways.

Experts reflect on interchangeability between oral and intravenous therapy in patients with higher-risk myelodysplastic syndromes.

Carl Schmid and Frank J. Palella, MD, discuss how coverage differs for medications vs ancillary service costs for HIV PrEP based on USPSTF guidelines.

Ryan Bitton, PharmD, MBA, and Frank J. Palella, MD, discuss facts about the implementation of USPSTF guidelines for HIV PrEP therapy.

Shared insight on the historical and current use of hypomethylating agents in patients with myelodysplastic syndromes.

Perspectives on the use of oral HMA therapy in higher-risk myelodysplastic syndromes, and how this has improved patient care.

Carl Schmid discusses the implications of the USPSTF Grade A rating of HIV PrEP to patients, providers, and payers.

Sean E. Bland, JD, reviews the USPSTF guidelines as support to access HIV PrEP therapy and Ryan Bitton, PharmD, MBA, shares a payer perspective on the implications of these guidelines.

Expert panelists discuss when it’s appropriate to consider or continue ESA therapy or blood transfusions in patients with MDS.

Panelists share insight on therapeutic goals when treating patients with myelodysplastic syndromes.

Carl Schmid shares steps that providers and payers can take to overcome access barriers for HIV PrEP therapy.

Sean E. Bland, JD, discusses barriers to access for eligible patients to receive HIV PrEP therapy.

A brief review of disease and patient factors that influence the selection of therapy for myelodysplastic syndromes.

Reflections on the historical use of ESAs and blood transfusions to treat patients with myelodysplastic syndromes.